Sitagliptin is the first selective DPP-4 inhibitor clinically used in 2006.6 Sitagliptin had pleiotropic effects in the treatment of patients with type 2 diabetes, including improved lipid parameters,7 but findings are inconsistent across studies. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.